Services
Services
Anticipate. Don't React.
Regulatory Strategy & Risk Assessment
The Challenge
Effective regulatory strategy begins well before an inspection. It requires a clear understanding of your current compliance posture, FDA priorities, and a plan that anticipates expectations rather than reacting to them.
Our principals directed inspection programs and enforcement actions organizations face today. We assess your operations through a regulator’s lens – identifying risks others miss and building programs that stand up under inspection.
What We Provide
- 503A and 503B tailored regulatory support
- Enterprise-level compliance and quality system assessment
- USP and CGMP compliance assessment
- Inspection readiness evaluation and preparation
- Risk-based surveillance analysis and proactive risk mitigation planning
- Recall strategy design and adverse event risk assessment
We've Sat Across the Table
Post-Inspection & Response
The Challenge
When the FDA acts, many organizations respond procedurally—addressing observations item by item without demonstrating a clear understanding of the underlying concern. That approach can escalate rather than resolve enforcement.
Our principals have been on the other side—evaluating responses, determining escalation, and deciding when enforcement was complete. We craft responses that are credible, well-positioned, and designed to close the enforcement cycle.
What We Provide
- Strategic development of Warning Letters and Untitled Letter responses
- Form 483 observation response strategy, drafting support, and review
- Regulatory meeting preparation
- Comprehensive gap analysis
The Why Behind the What
Policy & Compliance Program Development
The Challenge
The compounding sector is governed by an intricate web of federal statute, FDA guidance, USP standards, and state board requirements — and the interaction among these authorities is often where compliance programs fail. Building a program that works requires both regulatory breadth and practical depth.
Our principals have written the national policies that underpin today’s compliance expectations. That direct policy experience means we can design programs that don’t just meet the letter of the requirement — they reflect the intent behind it and are therefore far more durable under scrutiny.
What We Provide
- Compliance program architecture and design
- SOP framework evaluation, development strategy, and review
- FD&C Act compliance assessment and guidance
- Adverse event reporting strategy, program design, and implementation support
- Labeling review and compliance assessment
- Incident management program development
Signals. Not Surprises.
Compounding Intelligence and Surveillance
The Challenge
Staying ahead in compounding requires more than awareness—it requires insight into what is changing, why it matters, and what comes next. We monitor regulatory, enforcement, and policy developments across federal and state authorities, translating signals into clear, actionable intelligence. Our clients don’t just keep up—they stay ahead.
What We Provide
- Interpretation and analysis of emerging and existing policies and requirements
- Executive briefings on FDA enforcement trends, priorities, and horizon issues
- Advocacy strategy development and regulatory positioning
- Regulatory risk assessment for private equity investors and investment due diligence
- Strategic regulatory education and training
We Reduce Regulatory Risk. We Engineer Compliant Systems. We Protect Patients Through Process.
Assess
We evaluate your current compliance posture honestly and completely — identifying not just what’s visible, but what an experienced FDA inspector would see.
Strategize
We develop a strategy that addresses the root drivers of your regulatory risk — not just symptoms — with the policy context that transforms compliance into advantage.